公开(公告)号：US20240287488A1

公开(公告)日：2024-08-29

申请号：US18425174

申请日：2024-01-29

Applicant: The Regents of the University of California

Inventor： Karsten Zengler ,  Ajit Varki ,  Frederico Da Silva ,  Sandra Diaz ,  Cameron Martino ,  Geoffrey Chang ,  Steven Rees ,  Livia Soares Zaramela

IPC: C12N9/24 ,  A23C7/04 ,  A23L5/20 ,  A23L13/40 ,  A23L29/00 ,  A23L33/135 ,  A61K35/741 ,  A61K35/745 ,  A61K38/00 ,  A61K38/47 ,  C12N15/70

CPC classification number: C12N9/2402 ,  A23C7/043 ,  A23L5/25 ,  A23L13/48 ,  A23L29/06 ,  A23L33/135 ,  A61K35/741 ,  A61K35/745 ,  A61K38/00 ,  A61K38/47 ,  C12N15/70 ,  C12Y302/01018 ,  A23V2002/00 ,  A23V2400/517 ,  A23V2400/519 ,  A23V2400/529 ,  A23V2400/533

Abstract: The present disclosure relates to novel sialidase enzymes having a preference for cleaving N-glycolylneuraminic acid (Neu5Gc) from glycoconjugates over cleaving N-acetyineuraminic acid (Neu5Ac). The present disclosure further provides the polypeptide of such novel sialidase and its catalytic pockets; the recombinant host cells expressing the same, as well as the enzymatic, pharmaceutical, and consumable compositions comprising such novel sialidases. Probiotic compositions comprising a bacterium that expresses the sialidase having a preference for Neu5Gc over Neu5Ac, and methods for removing Neu5Gc from consumable products are also provided. Also disclosed are methods for treating or preventing various diseases, disorders, and inflammatory conditions in a subject using the novel sialidases.

公开(公告)号：US20210062171A1

公开(公告)日：2021-03-04

申请号：US17006293

申请日：2020-08-28

Applicant: The Regents of the University of California

Inventor： Karsten Zengler ,  Ajit Varki ,  Frederico Da Silva ,  Sandra Diaz ,  Cameron Martino ,  Geoffrey Chang ,  Steven Rees ,  Livia Soares Zaramela

IPC: C12N9/24 ,  A61K38/00 ,  A61K35/741 ,  A61K35/745 ,  A61K38/47 ,  A23L33/135 ,  A23L29/00 ,  A23L5/20 ,  A23L13/40 ,  A23C7/04

Abstract: The present disclosure relates to novel sialidase enzymes having a preference for cleaving N-glycolylneuraminic acid (Neu5Gc) from glycoconjugates over cleaving N-acetylneuraminic acid (Neu5Ac). The present disclosure further provides the polypeptide of such novel sialidase and its catalytic pockets; the recombinant host cells expressing the same, as well as the enzymatic, pharmaceutical, and consumable compositions comprising such novel sialidases. Probiotic compositions comprising a bacterium that expresses the sialidase having a preference for Neu5Gc over Neu5Ac, and methods for removing Neu5Gc from consumable products are also provided. Also disclosed are methods for treating or preventing various diseases, disorders, and inflammatory conditions in a subject using the novel sialidases.

公开(公告)号：US20230277634A1

公开(公告)日：2023-09-07

申请号：US18005816

申请日：2021-08-16

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Cameron Martino ,  Benjamin Kellman ,  Nathan Lewis ,  Robin Knight ,  Jeffrey D. Esko ,  Daniel Sandoval ,  Thomas Mandel Clausen

IPC: A61K38/51 ,  A61K35/74 ,  A61K38/46 ,  C12Q1/34 ,  C12Q1/527 ,  C12Q1/02 ,  A61P31/14

CPC classification number: A61K38/51 ,  A61K35/74 ,  A61K38/465 ,  C12Q1/34 ,  C12Q1/527 ,  C12Q1/02 ,  A61P31/14 ,  C12Y301/06013 ,  C12Y301/06014 ,  C12Y402/02007

Abstract: Methods and compositions for diagnosing, preventing or treating a viral infection in a subject comprising administering to a subject in need thereof an effective amount of a glycosidase or a sulfatase to degrade a glycan, such as heparan sulfate, to inhibit viral infection, such as COVID-19. Methods for identifying a glycosidase, a sulfatase, or a microbe associated with increased susceptibility to viral infection in a subject.